profit from every CHF 100 of sales.
CHF 0CHF 100
Medartis
CHF 108.80-0.73% today
+28.8% in 1 year
1-year low CHF 72.001-year high CHF 110.60
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay CHF 162.20 for every CHF 1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Medartis sold, what it kept, and what it did with the cash.
Sales went from CHF 183 million in 2022 to CHF 269 million in 2025, with CHF 8.35 million of profit last year.
SalesProfit
Medartis vs. similar companies
Medartis grows the fastest of these 5 and is the most expensive for its profits.
| Company | Profit from CHF 100 of sales | Sales growth a year | Price per CHF 1 of profit |
|---|---|---|---|
| Medartis | 162.2× · Very expensive | ||
 Abbott Laboratories | 28.5× · Fair price | ||
 Medtronic | 26.9× · Fair price | ||
 Stryker | 36.6× · Expensive | ||
 Edwards Lifesciences | 56.7× · Expensive |
AI analysis
An AI analyst reads Medartis's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CHF | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 183 | 212 | 225 | 269 | |
| 149 | 168 | 179 | 204 | |
| -2 | 8 | 7 | 2 | |
| 12 | 25 | 30 | 46 | |
| -6 | 1 | 4 | 8 | |
| -0.49 | 0.05 | 0.28 | 0.67 | |
| 81.8% | 79.0% | 79.5% | 75.9% | |
| -1.0% | 3.9% | 3.2% | 0.7% | |
| -3.2% | 0.3% | 1.6% | 3.1% |
Balance sheet
| In millions of CHF | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 328 | 350 | 460 | 560 |
| Cash | 21 | 25 | 139 | 33 |
| Total debt | 27 | 27 | 121 | 158 |
| Total liabilities | 90 | 95 | 190 | 284 |
| 238 | 255 | 270 | 276 | |
| 12 | 12 | 12 | 12 | |
| -2.1% | 0.8% | 1.7% | 4.0% | |
| -2.4% | 0.2% | 1.3% | 3.0% |
Cash flow
| In millions of CHF | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -4 | 20 | 32 | 35 | |
| 19 | 19 | 11 | 25 | |
| -23 | 1 | 21 | 9 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 1 | 1 | 2 |
Valuation
- 162.2×
- –
- –
- 3.4×
- 5.0×
- 145.0×
- 32.4×
- 0.7%
- 0.6%
- –
Profitability
- 75.9%
- 0.7%
- 3.1%
- –
- 4.0%
- 1.1%
- –
- –
- –
- –
Growth
- +13.8%
- –
- –
- –
- +1.7%
Financial health
- 2.7×
- 0.57
- –
- 2.7×
- 2.21
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 45%of 947
Bottom 30%of 872
Bottom 3%of 560
Top 42%of 866
Bottom 46%of 985
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
36No pass
Benjamin Graham
23No pass
Philip Fisher
38No pass
Peter Lynch
56No pass
Joel Greenblatt
1No pass
Charlie Munger
28No pass
Terry Smith
39No pass
Questions about Medartis
Is Medartis a good stock to buy?
A business with weak numbers, priced as if everything goes right. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Medartis AI analysis
What does Medartis do?
Medartis Holding AG, a medical device company, engages in the development, manufacturing, and sales of implant solutions worldwide. It is in Medical Devices, based in Basel, Switzerland, with 1,180 employees.
Is Medartis stock halal?
Yes. Medartis passes our halal screen: its business is permitted and its debt is 12% of its market value, under the 30% limit. How we check
How has Medartis stock done over the past year?
Up 28.8% over the past twelve months, to CHF 108.80. It traded between CHF 72.00 and CHF 110.60, close to its high.
Who are Medartis's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with Medartis's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.